While reporting financial results for the third quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and sales growth guidance for the full-year 2024. The company also provided forecast for the fourth quarter.
For fiscal 2024, the company now projects earnings in a range of $1.28 to $1.30 per share and adjusted earnings in a range of $2.45 to $2.47 per share on net sales growth of about 16.5 percent, with organic net sales growth of 15 percent.
Previously, the company expected earnings in the range of $1.34 to $1.38 per share and adjusted earnings in the range of $2.38 to $2.42 per share on net sales growth of about 13.5 to 14.5 percent, with organic net sales growth of 13 to 14 percent.
On average, 32 analysts polled by Thomson Reuters expect earnings of $2.41 per share on revenue growth of 14.4 percent to $16.29 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company estimates earnings in a range of $0.41 to $0.43 per share and adjusted earnings in a range of $0.64 to $0.66 per share on net sales growth of about 16.5 to 18.5 percent, with organic net sales growth of 14 to 16 percent.
Analysts expect earnings of $0.64 per share on revenue growth of 14.9 percent to $4.28 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.